CD55 - Cluster of Differentiation Antigen 55 Deficiency

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Eculizumab InjectionN/A1 trial
Active Trials
NCT03950804UnknownEst. Jun 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Allergy TherapeuticsEculizumab Injection

Clinical Trials (1)

NCT03950804Allergy TherapeuticsEculizumab Injection

Transcriptome and Metabolic Analyses of CHAPLE Disease

Start: Jun 2018Est. completion: Jun 2020
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space